Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06297616
Status:
RECRUITING
Last Update Posted:
2024-05-30
First Post:
2024-03-01
Brief Title:
A Study of LY3841136 in Japanese Participants With Obesity or Overweight
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Multiple-Ascending Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of LY3841136 Monotherapy and LY3841136 in Combination With Tirzepatide in Japanese Participants With Obesity or Overweight
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide when given to Japanese participants with obese or overweight Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body Part A of the study will last about 28 weeks and may include up to 17 visits Part B of the study will last about 40 weeks and may include up to 29 visits
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J3R-JE-YDAB | OTHER | Eli Lilly and Company | None |